Abstract:Abstract Esophageal adenocarcinoma (EAC) is a deadly disease with increased incidence in Western countries. More than half of EAC patients are diagnosed at an advanced stage, when curative surgery is not an option. Platinum- and fluorouracil (FU)-based chemo-radiation are the mainstay of treatments for advanced EAC with modest survival benefit but substantial toxicity. The lack of effective early detection tool and the low rate of treatment responses for advanced disease result in a dismal overall 5-year survival rate of <15%. Identification of minimally invasive, blood-based biomarkers for early diagnosis and prognosis/therapy response is essential to improve the overall outcome for EAC patients. In this study, we aimed to identify serum miRNAs as diagnostic and/or prognosis/predictive biomarkers for EAC. Firstly, a global screening of human miRNAs was conducted using TaqMan Human MicroRNA Microarray (754 miRNAs) in a pilot study. We selected 89 stably detectable miRNAs and measured their expression in 349 serum samples (165 cases vs184 controls) from Caucasian population using a newly designed Fluidigm BioMark™ customized panel. After quality control, 77 miRNAs were included in the final analysis. Five miRNAs (miR-126, miR-142-3p, miR-331-3p, miR-18a and miR-18) were significantly differentially-expressed between cases and controls (P<0.05). Among the 165 EAC patients, five miRNAs were significantly associated with survival and two with recurrence (P<0.05). Interestingly, higher miR-30c level was significantly associated with decreased risk for both death (HR=0.28, 95%CI= 0.12- 0.65, P= 0.003) and recurrence (HR= 0.49, 95%CI= 0.24- 0.99, P= 0.047). Among 118 patients received chemo/chemoradiation, 93% and 84% have received 5FU or platinum-agent, respectively. MiR-142-3p was associated with an increased risk of recurrence in the platinum-based subgroup (HR=2.67, 95%CI= 1.09- 6.56, P=0.032). Higher levels of miR-30c was associated with decreased risk of death in both treatment subgroups with a similar effect. MiR-26a was significantly associated with an increased risk of death (HR=5.78, 95%CI= 1.59-21.06, P=0.008) and recurrence (HR=7.76, 95%CI= 2.30-26.18, P=0.001) in the platinum subgroup, whereas miR-127-3p and miR-486-5p were significantly associated with both survival and recurrence in the 5FU subgroup. We further tested the expression of candidate serum miRNAs in tissue samples (15 normal and 81 tumor). Interestingly, miR-26a, which was significantly associated with increased risk of both death and recurrence in platinum subgroup, was overexpressed in tumor as compared to the normal tissue (P<0.001), suggesting a potential oncogenic feature for this miRNA. We are currently validating these results. Our study provides strong evidence to support the application of circulating miRNAs as minimally invasive early diagnosis and prognosis/predictive biomarkers for EAC. Citation Format: Xia Pu, Jian Gu, Yuanqing Ye, Jaffer Ajani, Xifeng Wu. Circulating miRNAs as potential biomarkers for esophageal adenocarcinoma risk and clinical outcomes. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2915. doi:10.1158/1538-7445.AM2014-2915

Cell-free Mir-24 and Mir-30D, Potential Diagnostic Biomarkers in Malignant Effusions.

Cell-free miRNAs may indicate diagnosis and docetaxel sensitivity of tumor cells in malignant effusions

Differential Proteome Profiling of Pleural Effusions from Lung Cancer and Benign Inflammatory Disease Patients

Genome-wide Microrna Expression Profiling in Malignant Pleural Effusion to Identify a Ten-Microrna Signature.

[Expression of Microrna-221/222 in Patients with Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma].

Cell-Free MicroRNA Expression Profiles in Malignant Effusion Associated with Patient Survival in Non-Small Cell Lung Cancer

Detection of Cell-Free BIRC5 Mrna in Effusions and Its Potential Diagnostic Value for Differentiating Malignant and Benign Effusions.

Exosomal Let-7D-3p and Mir-30D-5p As Diagnostic Biomarkers for Non-Invasive Screening of Cervical Cancer and Its Precursors

Salivary microRNAs show potential as biomarkers for early diagnosis of malignant pleural effusion

Circulating MicroRNA Panel As a Diagnostic Marker for Hepatocellular Carcinoma

MicroRNAs – novel biomarkers for malignant pleural effusions

The expression levels of VEGF and ICAM-1 in pleural effusion

Combined Detection of Carcinoembryonic Antigen and C-reactive Protein in Identifying Benign and Malignant Pleural Effusion

Diagnostic and Predictive Role of Cell-Free Midkine in Malignant Pleural Effusions

Cell-Free DNA and DNA integrity in malignant and benign effusions

Decreased Serum Mir-375 And Mir-320a Levels Are Useful In Predicting Liver Cancer

Metabonomic Classification and Detection of Small Molecule Biomarkers of Malignant Pleural Effusions

The Diagnostic Significance of the Detection of Cytokeratin 19 Mrna by Quantitative RT-PCR in Benign and Malignant Pleural Effusions

Abstract 2915: Circulating Mirnas As Potential Biomarkers for Esophageal Adenocarcinoma Risk and Clinical Outcomes

Research on the correlation of tumor markers in effusions with serum tumor markers and cytology examination

Proteomic study of benign and malignant pleural effusion